TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.

James Chih-Hsin Yang; Sanjay Popat; Panos Georgiou; Emiko Miyamoto; Jeffrey D. Isaacson; Heather A. Wakelee

doi:10.1200/jco.2015.33.15_suppl.tps8109

TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps8109 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS8109-TPS8109

Author(s):

James Chih-Hsin Yang ◽

Sanjay Popat ◽

Panos Georgiou ◽

Emiko Miyamoto ◽

Jeffrey D. Isaacson ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Cytotoxic Chemotherapy ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Egfr Tki ◽

Doublet Chemotherapy

Download Full-text

Abstract CT289: Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: Phase 3, randomized, open-label LEAP-008 trial

10.1158/1538-7445.am2020-ct289 ◽

2020 ◽

Author(s):

Natasha B. Leighl ◽

Rina Hui ◽

Delvys Rodríguez-Abreu ◽

Makoto Nishio ◽

Matthew D. Hellmann ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Previously Treated ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps3112 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS3112-TPS3112

Author(s):

Dingzhi Huang ◽

Ziping Wang ◽

Xinmin Yu ◽

Ying Cheng ◽

Jie Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Open Label ◽

Phase 3

Download Full-text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30641-0 ◽

2021 ◽

Vol 22 (2) ◽

pp. 198-211 ◽

Cited By ~ 2

Author(s):

Luis Paz-Ares ◽

Tudor-Eliade Ciuleanu ◽

Manuel Cobo ◽

Michael Schenker ◽

Bogdan Zurawski ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00134-x ◽

2021 ◽

Author(s):

Jianxing He ◽

Chunxia Su ◽

Wenhua Liang ◽

Shidong Xu ◽

Lin Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Adjuvant Treatment ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Egfr Mutant

Download Full-text

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00606-9 ◽

2021 ◽

Author(s):

Cecile Le Pechoux ◽

Nicolas Pourel ◽

Fabrice Barlesi ◽

Delphine Lerouge ◽

Delphine Antoni ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Postoperative Radiotherapy ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3

Download Full-text

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30339-x ◽

2017 ◽

Vol 18 (7) ◽

pp. 874-886 ◽

Cited By ~ 216

Author(s):

Alice T Shaw ◽

Tae Min Kim ◽

Lucio Crinò ◽

Cesare Gridelli ◽

Katsuyuki Kiura ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(16)32517-x ◽

2017 ◽

Vol 389 (10066) ◽

pp. 255-265 ◽

Cited By ~ 1731

Author(s):

Achim Rittmeyer ◽

Fabrice Barlesi ◽

Daniel Waterkamp ◽

Keunchil Park ◽

Fortunato Ciardiello ◽

...

Keyword(s):

Lung Cancer ◽

Randomised Controlled Trial ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Previously Treated ◽

Randomised Controlled

Download Full-text

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(18)32409-7 ◽

2019 ◽

Vol 393 (10183) ◽

pp. 1819-1830 ◽

Cited By ~ 522

Author(s):

Tony S K Mok ◽

Yi-Long Wu ◽

Iveta Kudaba ◽

Dariusz M Kowalski ◽

Byoung Chul Cho ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3

Download Full-text

Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.7035 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7035-7035 ◽

Cited By ~ 7

Author(s):

T. Cufer ◽

E. Vrdoljak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70184-x ◽

2011 ◽

Vol 12 (8) ◽

pp. 735-742 ◽

Cited By ~ 2256

Author(s):

Caicun Zhou ◽

Yi-Long Wu ◽

Gongyan Chen ◽

Jifeng Feng ◽

Xiao-Qing Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text